Ptc Therapeutics Stock Performance
| PTCT Stock | USD 46.15 0.93 2.06% |
On a scale of 0 to 100, PTC Therapeutics holds a performance score of 6. The company owns a Beta (Systematic Risk) of 0.64, which implies possible diversification benefits within a given portfolio. As returns on the market increase, PTC Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding PTC Therapeutics is expected to be smaller as well. Please check PTC Therapeutics' value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether PTC Therapeutics' current price history will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in PTC Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating fundamental indicators, PTC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.0664 | Five Day Return (1.70) | Year To Date Return (1.44) | Ten Year Return (18.42) | All Time Return 174.23 |
1 | PTC Therapeutics Inc Q3 2024 Earnings Call Highlights Revenue Growth and Strategic ... | 11/08/2024 |
2 | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 11/25/2024 |
3 | PTC Therapeutics Hits New 1-Year High on Analyst Upgrade | 12/03/2024 |
4 | PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, H... | 12/11/2024 |
5 | The Global Medical Cannula Market Is Poised for Significant Growth USD 447.0 Million by 2034 at a 6.9 percent of CAGR, driven by Rising Demand for Medical Proce... | 12/16/2024 |
6 | PTC Therapeutics Submits NDA for Vatiquinone to FDA for Friedreich Ataxia Treatment | 12/19/2024 |
7 | PTC Therapeutics to Present at J.P. Morgan Healthcare Conference | 12/23/2024 |
8 | Acquisition by Klein Matthew B. of 175000 shares of PTC Therapeutics at 46.54 subject to Rule 16b-3 | 01/03/2025 |
9 | Disposition of 107 shares by Neil Almstead of PTC Therapeutics at 44.5 subject to Rule 16b-3 | 01/08/2025 |
10 | Orsini the Exclusive Specialty Pharmacy Provider for Gene Therapy KEBILIDI | 01/14/2025 |
11 | Acquisition by Eric Pauwels of 55000 shares of PTC Therapeutics at 46.54 subject to Rule 16b-3 | 01/17/2025 |
| Begin Period Cash Flow | 295.9 M |
PTC |
PTC Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,047 in PTC Therapeutics on November 1, 2024 and sell it today you would earn a total of 568.00 from holding PTC Therapeutics or generate 14.04% return on investment over 90 days. PTC Therapeutics is currently generating 0.2805% in daily expected returns and assumes 3.6194% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than PTC, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PTC Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PTC Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PTC Therapeutics, and traders can use it to determine the average amount a PTC Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0775
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PTCT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.62 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average PTC Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PTC Therapeutics by adding it to a well-diversified portfolio.
PTC Therapeutics Fundamentals Growth
PTC Stock prices reflect investors' perceptions of the future prospects and financial health of PTC Therapeutics, and PTC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PTC Stock performance.
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.87 B | ||||
| Shares Outstanding | 77.13 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 3.87 X | ||||
| Revenue | 937.82 M | ||||
| Gross Profit | 299.37 M | ||||
| EBITDA | (330.34 M) | ||||
| Net Income | (626.6 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 2.23 B | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (13.70) X | ||||
| Cash Flow From Operations | (158.42 M) | ||||
| Earnings Per Share | (5.94) X | ||||
| Market Capitalization | 3.49 B | ||||
| Total Asset | 1.9 B | ||||
| Retained Earnings | (3.28 B) | ||||
| Working Capital | 615.53 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
About PTC Therapeutics Performance
Assessing PTC Therapeutics' fundamental ratios provides investors with valuable insights into PTC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the PTC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 195.99 | 186.19 | |
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.31) | (0.30) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | 0.88 | 0.92 |
Things to note about PTC Therapeutics performance evaluation
Checking the ongoing alerts about PTC Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PTC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PTC Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 937.82 M. Net Loss for the year was (626.6 M) with profit before overhead, payroll, taxes, and interest of 299.37 M. | |
| PTC Therapeutics currently holds about 288.43 M in cash with (158.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Orsini the Exclusive Specialty Pharmacy Provider for Gene Therapy KEBILIDI |
- Analyzing PTC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PTC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining PTC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PTC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PTC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PTC Therapeutics' stock. These opinions can provide insight into PTC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.